NicoxNICXF 37 Current Ratio is 4.18 as of Dec. 2025, which is 14% below its 10-year median of 4.87. GuruFocus rates NICXF with a GF Score™ of 37/100 and a GF Value™ of $0.56. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Nicox ranks better than 51.84% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nicox's current ratio for the quarter that ended in Dec. 2025 was 4.18.
Nicox has a current ratio of 4.18. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Nicox's Current Ratio or its related term are showing as below:
NICXF'
s Current Ratio Range Over the Past 10 Years
Min: 2.29 Med: 4.87 Max: 10.09
Current: 4.18
During the past 13 years, Nicox's highest Current Ratio was 10.09. The lowest was 2.29. And the median was 4.87.
NICXF's Current Ratio is ranked better than 51.84% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs NICXF: 4.18
Nicox (OTCPK:NICXF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nicox Current Ratio Related Terms
Nicox Current Ratio Historical Data
* Premium members only.
The historical data trend for Nicox's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NICXF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Nicox's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nicox Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nicox's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nicox's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nicox (NICXF) has a Current Ratio of 4.18 as of Dec. 2025. This is 14% below median its historical median of 4.87. Over the past decade, Nicox's Current Ratio has ranged from 2.29 to 10.09. According to the industry distribution chart, Nicox ranks #680 out of 1412 companies in the Biotechnology industry, placing it in the top 48.2%.
Is Nicox's Current Ratio too high?
Nicox's current Current Ratio of 4.18 is 14% below median its 10-year median of 4.87. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 10.09. The Biotechnology industry median Current Ratio is 3.89. Nicox's value of 4.18 is 7.5% above this industry median. Based on the distribution chart, Nicox ranks #680 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nicox has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Nicox's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nicox ranks #680 out of 1412 companies for Current Ratio. This puts Nicox in the upper half of its industry. The industry median Current Ratio is 3.89. Nicox's value of 4.18 is 7.5% above this benchmark. Historically, Nicox's own Current Ratio has ranged from 2.29 to 10.09 over the past decade. While the company's 10-year median is 4.87 vs. the industry median of 3.89, Nicox has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nicox's current Current Ratio of 4.18 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nicox's current Current Ratio is 4.18, which is 14% below median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nicox stock overvalued right now?
Nicox (NICXF) has a current Current Ratio of 4.18. The stock's GF Value™ is $0.56, compared to a current price of $0.30 — trading 46.4% below its estimated fair value. The current Current Ratio is 4.18, which is 14% below median its 10-year median of 4.87 and 7.5% above the Biotechnology industry median of 3.89. Nicox's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nicox (NICXF), the current Current Ratio is 4.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nicox (NICXF) Overvalued in 2026?
Based on GuruFocus' analysis, Nicox stock appears to be undervalued.
The current stock price of $0.30 is trading 46.4% below its estimated GF Value™ of $0.56.
Key valuation signals for NICXF:
Current Ratio: 4.18 (14% below median its 10-year median of 4.87)
GF Value™: $0.56 vs. price of $0.30 (46.4% below fair value)
Industry Position: 7.5% above the Biotechnology median (#680 of 1412)
No single metric tells the full story. See the NICXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
37GF Score
Get the complete analysis for NICXF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NICXF has been successfully added to your 
